Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.

Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM.

Nat Commun. 2017 Jul 17;8:15981. doi: 10.1038/ncomms15981.

2.

Therapeutic targeting and patient selection for cancers with homologous recombination defects.

Talens F, Jalving M, Gietema JA, Van Vugt MA.

Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2. Review.

PMID:
28425306
3.

Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.

Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F.

Mol Cancer Res. 2018 Jul;16(7):1092-1102. doi: 10.1158/1541-7786.MCR-18-0106. Epub 2018 Mar 28.

4.

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.

Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.

Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.

5.

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR.

Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21.

6.
7.

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.

Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M.

Oncotarget. 2016 Feb 16;7(7):7701-14. doi: 10.18632/oncotarget.6715.

8.

The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX.

Int J Biol Sci. 2006;2(4):179-85. Epub 2006 Jun 10.

9.

Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.

Sunada S, Nakanishi A, Miki Y.

Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6. Review.

10.

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.

Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

11.

[BRCA1 and BRCA2 - pathologists starting kit].

Škapa P.

Cesk Patol. Fall 2016;52(4):193-196. Czech.

PMID:
27869444
12.

Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.

Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F.

Invest New Drugs. 2017 Jun;35(3):251-259. doi: 10.1007/s10637-016-0424-x. Epub 2017 Jan 23.

PMID:
28111726
13.

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.

14.

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.

Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H.

Oncogene. 2018 Jan 18;37(3):341-351. doi: 10.1038/onc.2017.326. Epub 2017 Sep 25.

15.

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.

Węsierska-Gądek J, Zulehner N, Ferk F, Składanowski A, Komina O, Maurer M.

Biochem Pharmacol. 2012 Nov 15;84(10):1318-31. doi: 10.1016/j.bcp.2012.07.024. Epub 2012 Aug 14.

16.

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

Kyle S, Thomas HD, Mitchell J, Curtin NJ.

Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297.

PMID:
18820000
17.

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.

Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B.

Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.

PMID:
25975349
18.

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.

Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.

19.

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.

Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC.

Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.

20.

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S.

Cancer Discov. 2013 Jan;3(1):68-81. doi: 10.1158/2159-8290.CD-12-0049. Epub 2012 Oct 25.

Supplemental Content

Support Center